We identified two prognostic clusters of MIBC, with the shorter overall survival subtype showing higher burden of large‐scale SCNAs and WGD, higher prevalence of mutations in TP53 and RB1, higher levels of intra‐tumor heterogeneity as well as suppressed tumor microenvironment and higher rate of developing metastatic disease. The gene discussed is TP53; the disease is metastatic neoplasm.